JP2022552159A5 - - Google Patents

Info

Publication number
JP2022552159A5
JP2022552159A5 JP2022520601A JP2022520601A JP2022552159A5 JP 2022552159 A5 JP2022552159 A5 JP 2022552159A5 JP 2022520601 A JP2022520601 A JP 2022520601A JP 2022520601 A JP2022520601 A JP 2022520601A JP 2022552159 A5 JP2022552159 A5 JP 2022552159A5
Authority
JP
Japan
Prior art keywords
salt
compound according
formula
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520601A
Other languages
English (en)
Japanese (ja)
Other versions
JP7545467B2 (ja
JP2022552159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053886 external-priority patent/WO2021067657A1/en
Publication of JP2022552159A publication Critical patent/JP2022552159A/ja
Publication of JP2022552159A5 publication Critical patent/JP2022552159A5/ja
Application granted granted Critical
Publication of JP7545467B2 publication Critical patent/JP7545467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520601A 2019-10-04 2020-10-02 置換カルバゾール化合物 Active JP7545467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910671P 2019-10-04 2019-10-04
US62/910,671 2019-10-04
PCT/US2020/053886 WO2021067657A1 (en) 2019-10-04 2020-10-02 Substituted carbazole compounds

Publications (3)

Publication Number Publication Date
JP2022552159A JP2022552159A (ja) 2022-12-15
JP2022552159A5 true JP2022552159A5 (enExample) 2023-10-10
JP7545467B2 JP7545467B2 (ja) 2024-09-04

Family

ID=73014623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520601A Active JP7545467B2 (ja) 2019-10-04 2020-10-02 置換カルバゾール化合物

Country Status (7)

Country Link
US (1) US12384760B2 (enExample)
EP (1) EP4038059B1 (enExample)
JP (1) JP7545467B2 (enExample)
KR (1) KR20220079587A (enExample)
CN (1) CN114829350B (enExample)
ES (1) ES2965164T3 (enExample)
WO (1) WO2021067657A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
JP7761316B2 (ja) * 2021-10-27 2025-10-28 ヒューケムバイオ株式会社 新規三誘導体化合物およびその用途
KR102548888B1 (ko) * 2021-10-27 2023-07-03 주식회사 휴켐바이오 신규한 트리사이클릭 유도체 화합물 및 이의 용도
US11807607B1 (en) 2023-03-09 2023-11-07 King Faisal University Aminocarbazole compounds as antibacterial agents
US11780809B1 (en) 2023-03-09 2023-10-10 King Faisal University Carbazole compounds as antibacterial agents

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
DK1474425T3 (da) 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
WO2007115306A2 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
DK1899333T3 (da) 2005-06-27 2009-06-15 Sanofi Aventis Pyrazolopyridinderivater som inhibitorer af beta-adrenerg receptor-kinase 1
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
NO2453895T3 (enExample) 2009-07-16 2018-10-20
ES2736200T3 (es) * 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
EP3208263A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014025114A1 (ko) 2012-08-10 2014-02-13 주식회사 두산 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3080124A1 (en) 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
EP3183251A4 (en) 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
RS59707B1 (sr) * 2014-10-24 2020-01-31 Bristol Myers Squibb Co Derivati karbazola
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
KR102519535B1 (ko) * 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
CN111448190B (zh) * 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
FI3728252T3 (fi) 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
BR112020012084A2 (pt) * 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos de indol substituído úteis como inibidores de tlr
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CN109867662B (zh) * 2018-02-07 2020-08-14 南方医科大学 一种咔唑β-氨基醇类衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022552159A5 (enExample)
JP2021534108A5 (enExample)
JP2012503621A5 (enExample)
JP2020505402A5 (enExample)
JP2008533152A5 (enExample)
JP2024512154A5 (enExample)
RU2002131941A (ru) 3-азот-6,7-дикислородсодержащие стероиды и их применение
RU2011101774A (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2004507513A5 (enExample)
JP2007532479A5 (enExample)
RU2015122757A (ru) Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
RU97105381A (ru) Соединения и способы для лечения рака
RU2000124100A (ru) Лиганды рецептора h3 гистамина
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2006520397A5 (enExample)
RU2001105910A (ru) Лиганды с высоким сродством к ноцицептиновому рецептору orl-1
JP2023512557A5 (enExample)
JP2020505400A5 (enExample)
JP2001526218A5 (enExample)
JP2021530442A5 (enExample)
JP2020505393A5 (enExample)
CA2506242A1 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
JP2005508961A5 (enExample)
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич